Cargando…

The clinicopathological characteristics of muscle‐invasive bladder recurrence in upper tract urothelial carcinoma

This study aimed to clarify the clinical characteristics and oncological outcomes of patients with upper tract urothelial carcinoma (UTUC) who developed muscle‐invasive bladder cancer (MIBC) after radical nephroureterectomy (RNU). We identified 966 pTa‐4N0‐2M0 patients with UTUC who underwent RNU an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shigeta, Keisuke, Matsumoto, Kazuhiro, Ogihara, Koichiro, Murakami, Tetsushi, Anno, Tadatsugu, Umeda, Kota, Izawa, Mizuki, Baba, Yuto, Sanjo, Tansei, Shojo, Kazunori, Tanaka, Nobuyuki, Takeda, Toshikazu, Kosaka, Takeo, Mizuno, Ryuichi, Mikami, Shuji, Kikuchi, Eiji, Oya, Mototsugu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935810/ https://www.ncbi.nlm.nih.gov/pubmed/33368857 http://dx.doi.org/10.1111/cas.14782

Ejemplares similares

Profiling the Biological Characteristics and Transitions through Upper Tract Tumor Origin, Bladder Recurrence, and Muscle-Invasive Bladder Progression in Upper Tract Urothelial Carcinoma
por: Shigeta, Keisuke, et al.
Publicado: (2022)

Role of the MUC1‐C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma
por: Shigeta, Keisuke, et al.
Publicado: (2020)

IDH2 stabilizes HIF‐1α‐induced metabolic reprogramming and promotes chemoresistance in urothelial cancer
por: Shigeta, Keisuke, et al.
Publicado: (2023)

Oncological outcomes of dose reductions in cisplatin due to renal dysfunction for patients with metastatic urothelial carcinoma
por: Murakami, Tetsushi, et al.
Publicado: (2021)

A Japanese patient with ductal carcinoma of the prostate carrying an adenomatosis polyposis coli gene mutation: a case report
por: Umeda, Kota, et al.
Publicado: (2020)

A Case of Bladder-Inverted Papilloma after Brachytherapy for Prostate Cancer
por: Ezaki, Taisuke, et al.
Publicado: (2014)

Sulfasalazine could modulate the CD44v9‐xCT system and enhance cisplatin‐induced cytotoxic effects in metastatic bladder cancer
por: Ogihara, Koichiro, et al.
Publicado: (2019)

A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations
por: Kobayashi, Hiroaki, et al.
Publicado: (2021)

First case of ductal adenocarcinoma of the prostate with MAP3K1 homozygous deletion
por: Shojo, Kazunori, et al.
Publicado: (2021)

Urinary pH is an independent predictor of upper tract recurrence in non-muscle-invasive bladder cancer patients with a smoking history
por: Ide, Hiroki, et al.
Publicado: (2021)

Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer
por: Masuda, Tsukasa, et al.
Publicado: (2022)

Pulmonary metastasis secondary to abiraterone‐resistant prostate cancer with homozygous deletions of BRCA2: First Japanese case
por: Izawa, Mizuki, et al.
Publicado: (2020)

Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer
por: Hagiwara, Masayuki, et al.
Publicado: (2018)

Predictors of Survival in Favorable Risk Patients with Metastatic Renal Cell Carcinoma Treated with a Single-Agent First-Line Therapy
por: Mizuno, Ryuichi, et al.
Publicado: (2022)

CDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression
por: Yanai, Yoshinori, et al.
Publicado: (2020)

Single‐cell RNA‐seq analysis reveals the platinum resistance gene COX7B and the surrogate marker CD63
por: Tanaka, Nobuyuki, et al.
Publicado: (2018)

Castration-resistant prostate cancer patient presenting with whole genome doubling with CDK-12 mutation
por: Baba, Yuto, et al.
Publicado: (2022)

Brachytherapy seeds as a nidus for urethral stone formation: A case report
por: Kamisawa, Ken, et al.
Publicado: (2019)

Cranial nerve palsy caused by metastasis to the skull base in patients with castration‐resistant prostate cancer: Three case reports
por: Yasumizu, Yota, et al.
Publicado: (2021)

Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways
por: Hongo, Hiroshi, et al.
Publicado: (2021)

Squamous cell carcinoma of the prostate with SMARCA4 alteration in a Japanese patient
por: Kaneko, Yuta, et al.
Publicado: (2022)

The first Japanese case of intraductal cancer of the prostate with checkpoint kinase 2 mutation
por: Hongo, Hiroshi, et al.
Publicado: (2022)

No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer
por: Kosaka, Takeo, et al.
Publicado: (2018)

Tumor budding, a novel prognostic indicator for predicting stage progression in T1 bladder cancers
por: Fukumoto, Keishiro, et al.
Publicado: (2016)

CD8-positive T cells and CD204-positive M2-like macrophages predict postoperative prognosis of very high-risk prostate cancer
por: Yanai, Yoshinori, et al.
Publicado: (2021)

PKM2 under hypoxic environment causes resistance to mTOR inhibitor in human castration resistant prostate cancer
por: Yasumizu, Yota, et al.
Publicado: (2018)

Predictors of urinary function recovery after laparoscopic and robot-assisted radical prostatectomy
por: Hakozaki, Kyohei, et al.
Publicado: (2022)

Bisebromoamide, an extract from Lyngbya species, induces apoptosis through ERK and mTOR inhibitions in renal cancer cells
por: Suzuki, Kenjiro, et al.
Publicado: (2013)

A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutation
por: Kosaka, Takeo, et al.
Publicado: (2019)

Vasohibin-1 expression as a biomarker of aggressive nature in ductal adenocarcinoma of the prostate: a retrospective cohort study at two centres in Japan
por: Kobayashi, Hiroaki, et al.
Publicado: (2021)

Germline BRCA2 mutation in a case of aggressive prostate cancer accompanied by spinal bulbar muscular atrophy
por: Hongo, Hiroshi, et al.
Publicado: (2021)

Prominent response to platinum‐based chemotherapy in a patient with BRCA2 mutant‐neuroendocrine prostate cancer and MDM2 amplification
por: Daimon, Tatsuaki, et al.
Publicado: (2021)

First successful case of platinum‐based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations
por: Omura, Minami, et al.
Publicado: (2021)

A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report
por: Iwasawa, Tomohiro, et al.
Publicado: (2022)

Negative impact of neoadjuvant hormonal therapy on detecting biochemical recurrence after radical prostatectomy
por: Matsumoto, Kazuhiro, et al.
Publicado: (2021)

Prognostic significance of 5-fluorouracil metabolism-relating enzymes and enhanced chemosensitivity to 5-fluorouracil by 5-chloro 2,4-dihydroxy-pyridine in urothelial carcinoma
por: Ide, Hiroki, et al.
Publicado: (2012)

Accidental Hypothermia Treated by Hemodialysis in the Acute Phase: Three Case Reports and a Review of the Literature
por: Murakami, Tetsushi, et al.
Publicado: (2019)

Optimal surgical treatment for paratesticular leiomyosarcoma: retrospective analysis of 217 reported cases
por: Kamitani, Rei, et al.
Publicado: (2022)

Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy
por: Komori, Takahiro, et al.
Publicado: (2022)

Is DHT Production by 5α-Reductase Friend or Foe in Prostate Cancer?
por: Kosaka, Takeo, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_e8l9edkn1ppgtkiph47df6vd1l